Shionogi Stays The Course As It Lays Out R&D Priorities
Executive Summary
Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.
You may also be interested in...
Prophylaxis Results Set Stage For Expanded Japan Xofluza Use
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.
Blackstone Bets On Pharma In First Japan Buy, But Why?
Major private equity group Blackstone buys into pharma for its first acquisition in Japan, but amid challenges in the sector, the attractions take some unraveling.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.